Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00867113
Other study ID # CSTI571BUS282
Secondary ID
Status Completed
Phase Phase 2
First received March 20, 2009
Last updated March 9, 2018
Start date July 22, 2009
Est. completion date December 20, 2016

Study information

Verified date March 2018
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST.


Description:

This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The primary endpoint is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST. A total of 85 adult patients, 18 years of age and older will be enrolled.Participants will take 400 mg of imatinib mesylate daily by mouth for a total of 5 years. At the conclusion of the treatment period, patients will be followed for 2 years for survival, status of response and antineoplastic treatments and quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date December 20, 2016
Est. primary completion date December 20, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients 18 years of age or older.

2. Patient must have had a histological diagnosis of primary GIST.

3. The tumor must expressed KIT (CD117) protein by immunohistochemistry performed by central pathology.

4. Patient must have been at significant risk of tumor recurrence as defined by either:

- Primary GIST (any site): = 2 cm and a mitotic rate of = 5/50 HPF's

- Non-gastric primary GIST: = 5cm

5. Patient must have undergone complete gross resection of a primary GIST within 12 weeks prior to first dose of imatinib study drug. The inclusion of R1 resections will be reviewed on a case by case basis by the Study Management Committee.

6. Patient must had no evidence of metastatic GIST on either 1) a post-operative CT of the abdomen and pelvis with intravenous and oral contrast or 2) MRI of the abdomen and pelvis with intravenous contrast. CT or MRI must have been performed within 8 weeks prior to first dose of imatinib study drug.

7. Performance status 0 or 1 (ECOG)

8. Patient must had the following post-operative laboratory values confirmed within 14 days prior to first dose of imatinib study drug:

- total bilirubin < 1.5 x ULN NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study.

- ALT and AST < 2.5 x ULN

- creatinine < 1.5 x ULN

- ANC > 1.5 x 109/L

- platelets > 100 x 109/L

9. If patient is a cancer survivor, ALL of the following criteria apply:

- Patient had undergone potentially curative therapy for all prior malignancies.

- No evidence of any prior malignancies for at least 3 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone).

- Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.

10. Female patients of childbearing potential must have had negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of reproductive potential must have jagreed to employ an effective barrier method of birth control throughout the study and for up to 7 days following discontinuation of study drug.

11. Written, voluntary informed consent.

Exclusion Criteria:

1. Patient has metastatic GIST to the peritoneum, liver, lymph node, or other sites or recurrent GIST.

2. Prior treatment for GIST with the exception of prior treatment with imatinib adjuvant lasting = 8 weeks following gross surgical resection.

3. Patient has received any other investigational agents within 28 days of first day of study drug dosing.

4. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)

5. Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risk or compromise compliance with the protocol (i.e., uncontrolled diabetes, chronic renal disease, chronic liver disease, or active uncontrolled infection).

6. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

7. Patient receiving concurrent treatment with warfarin (acceptable alternative: low-molecular weight heparin).

8. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

Study Design


Intervention

Drug:
imatinib mesylate
imatinib mesylate was supplied in 100 and 400 mg tablets

Locations

Country Name City State
United States University Cancer & Blood Center, LLC Athens Georgia
United States University of Colorado University of Colorado Aurora Colorado
United States Dana Farber Cancer Institute Dana-Farber Boston Massachusetts
United States Kootenai Medical Center Kootenai Cancer Cancer Coeur d'Alene Idaho
United States Karmanos Cancer Institute Karmonos Cancer Instit. (40) Detroit Michigan
United States Duke University Medical Center Duke University Med Ctr (8) Durham North Carolina
United States North Shore University Health System Evanston Illinois
United States Longstreet Cancer Center Gainesville Georgia
United States Penn State University / Milton S. Hershey Medical Center Penn Stat University Hershey Pennsylvania
United States MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (4) Houston Texas
United States Kingport Hematology Oncology Kingsport Tennessee
United States University of California San Diego - Moores Cancer Center Moores UCSD Cancer Center (31) La Jolla California
United States Southern Nevada Cancer Research Foundation S. Nevada Cancer Res (2) Las Vegas Nevada
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (7) New York New York
United States Virginia Oncology Associates Viriginia Oncology Assoc. Norfolk Virginia
United States Oregon Health & Science University OHS University Portland Oregon
United States Roger Williams Medical Center Medical Center Providence Rhode Island
United States Washington University School of Medicine Center for Advanced Medicine Saint Louis Missouri
United States South Texas Oncology and Hematology, PA South Texas Onc/Hem San Antonio Texas
United States Washington Hospital Center Department of Medical Oncology Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence-free Survival up to 60 Months Recurrence-free survival assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). Baseline up to 60 months
Primary Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months Recurrence-free survival (RFS) assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event). RFS estimates were summarized using the Kaplan-Meier product-limit method (Kaplan 1958). Censoring rules for RFS with the earliest occurring rule used in the analysis: subjects without objective recurrence of disease who were alive at the time of their discontinuation from study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment and subjects recording antineoplastic therapy during the study were censored on the date of the therapy initiated Baseline up to 60 months
Secondary Overall Survival (OS) at 60 Months Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set. Baseline up to approximately 60 months
Secondary Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set. Baseline up to appoximately 60 months
See also
  Status Clinical Trial Phase
Completed NCT02574663 - TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT01991379 - MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT00623831 - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Phase 1
Completed NCT01294202 - A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST Phase 2
Completed NCT00785785 - A Study of Nilotinib Versus Imatinib in GIST Patients Phase 3
Recruiting NCT02443948 - Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) N/A
Recruiting NCT01034670 - Advanced Gastrointestinal Endoscopic Imaging N/A
Active, not recruiting NCT01391611 - Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) Phase 2
Terminated NCT02452424 - A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT03594422 - A Study of HQP1351 in Patients With GIST or Other Solid Tumors Phase 1
Recruiting NCT05453292 - Endoscopic Ultrasound Radiofrequency Ablation for GISTs N/A
Completed NCT00780494 - Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Phase 2
Recruiting NCT04557969 - Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Completed NCT03404076 - Unifying Advanced Treatment With Advanced Imaging
Recruiting NCT04821895 - Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
Completed NCT01316263 - A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Recruiting NCT01048281 - Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma